Alnylam Pharmaceuticals

ALNY • NASDAQ • Stock Fundamentals

Alnylam Pharmaceuticals is a global commercial-stage biopharmaceutical company that pioneered the development of RNA interference (RNAi) therapeutics. The company utilizes small interfering RNA (siRNA) to silence specific messenger RNA (mRNA) molecules, preventing the production of disease-causing proteins. Their platform focuses on genetic medicines for rare and prevalent diseases, leveraging proprietary delivery technologies like GalNAc conjugates and lipid nanoparticles.

Market Cap$39.2B

Revenue TTM$4.3B

Net Income TTM$538.0M

P/E Ratio72.83

Net Margin12.55%

EPS TTM$3.98

Free Cash Flow TTM$643.3M

Employees2.1K

CEOYvonne L. Greenstreet

CountryUnited States of America

Healthcare

Biotechnology

SegmentsBiotechnology, Pharmaceuticals, Genetic Medicine

Business ModelsR&D-driven drug development, Product licensing, Direct product sales

Most Recent EarningsApr 30, 2026 · 16 days agoQ1 2026

View report

Next EarningsJul 30, 2026 · in 2 monthsBefore Market Open · Q2 2026

Income Statement Balance Sheet Cash Flow Segments

Financials

Based on Q1 2026 filing

View all metrics

Gross Margin81.0%

Op. Margin17.54%

ROE71.66%

D/E24.52%

Current Ratio3.13

Total Debt$263.7M

Cash$1.7B

CapEx TTM$71.6M

Business Segments

View segment metrics

Commercial Medicines

primary

The primary revenue-generating division focused on the global commercialization of approved RNAi therapeutics for rare and specialty diseases. This segment manages product sales, patient access, and marketing for the company's first-in-class portfolio.

Products

AMVUTTRA, ONPATTRO, GIVLAARI, OXLUMO, Leqvio, Qfitlia

Customers

Specialized medical centers, Hospitals, Pharmacies, Government healthcare agencies

Research and Development

moderate

Focuses on advancing a pipeline of siRNA candidates through clinical trials and developing novel delivery platforms for extrahepatic tissues. This segment targets indications in the central nervous system, ocular, and cardiovascular therapeutic areas.

Products

vutrisiran, patisiran, givosiran, lumasiran, inclisiran, fitusiran

Customers

Clinical trial participants, Research institutions, Strategic pharmaceutical partners

Business Overview

Competitive Position

Alnylam is the industry leader in RNAi therapeutics, holding the first-mover advantage with multiple approved products and a dominant intellectual property position in siRNA delivery.

Geographies

United States, European Union, Global

Customer Segments

Healthcare providers, Patients with rare genetic diseases, Global pharmaceutical companies

Upstream Dependencies

Specialized chemical suppliers, Contract manufacturing organizations, Genomic research databases

Downstream Customers

Wholesale drug distributors, Specialty pharmacies, Health insurance providers, Public health systems

Competitors & Partners

Competitors

Moderna

MRNA

Competitor in mRNA and nucleic acid delivery technologies

Ionis Pharmaceuticals

IONS

Competitor in antisense and RNA-targeted therapies

Arrowhead Research

ARWR

Competitor developing RNAi-based therapeutics

Similar Companies

Amgen

AMGN

Bristol-Myers Squibb

BMY

Regeneron Pharmaceuticals

REGN

AbbVie

ABBV

Gilead Sciences

GILD

Merck & Co.

MRK

Pfizer

PFE

Johnson & Johnson

JNJ

Abbott

ABT

Eli Lilly

LLY

Vertex Pharmaceuticals

VRTX

Partners

NVS

Novartis

NVS

Collaboration partner for the development and commercialization of Leqvio (inclisiran)

SNY

Sanofi

SNY

Strategic collaborator for fitusiran and other rare disease programs

Regeneron Pharmaceuticals

REGN

Collaboration for CNS and ocular RNAi therapeutics

ALN